Pablo Garcia de la Riva Mestre

M2RLAB, a biotech spin-off from IIBB-CSIC with a patented cell therapy platform that induces the polarization of monocytes to a new and curative phenotype. Using this platform, M2RLAB has developed an cell therapy that is indicated for different diseases of an acute and inflammatory nature, where fibrosis is involved. We have set up a centralized production facility that will allow to scalate production and sales in the future. We have innovated to bring an advanced cell therapy without the hastles in quality, production and logistics suffered by any other advanced cell therapy. We have obtained approval to initiate a Phase I/II clinical trial for our first product is M2R®-AKICELL. A first-in-class cellular medicine for the treatment of the incurable condition AKI. It is a therapy that does not fight against a specific molecular mechanism or pathway, but favors a decrease of inflammation and activates simultaneously mechanisms regenerating damaged tissue, thus avoiding or significantly decreasing the processes of necrosis and fibrosis that follow kidney aggression. Production of the therapy is centralized and scalable. Market launch of AKICELL is forecasted for late 2029 and we plan to start licensing in 2025. Other clinical lines of work include ARDS and Lupus Nephritis.